Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026162 | 0.84 | CLK4 (0.78) | TRPV1CLK4 | |
| SCHEMBL3099695 | 0.81 | CLK4 (0.69) | TRPV1CLK4 | |
| SCHEMBL31119240 | 0.81 | TRPV1 (0.66) | TRPV1 | |
| SCHEMBL3101886 | 0.81 | TRPV1 (0.66) | TRPV1 | |
| SCHEMBL5024919 | 0.80 | CLK4 (0.77) | TRPV1CLK4 | |
| SCHEMBL3095267 | 0.79 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL5026128 | 0.79 | CLK4 (1.00) | TRPV1CLK4 | |
| SCHEMBL5015997 | 0.78 | CLK4 (0.71) | TRPV1CLK4 | |
| SCHEMBL5024906 | 0.78 | CLK4 (0.70) | TRPV1CLK4 | |
| SCHEMBL5018035 | 0.77 | CLK4 (0.79) | TRPV1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815930-B2 | Compounds that inhibit TRPV1 and uses thereof | ABBVIE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20100249203-A1 | COMPOUNDS THAT INHIBIT TRPV1 AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-7767705-B2 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | ABBOTT LABORATORIES (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080058401-A1 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249203-A1 | COMPOUNDS THAT INHIBIT TRPV1 AND USES THEREOF | TRPV1, TRPV3, TRPA1 | TRPV1 1/4885CLK4 4568/4885 |
| US-20080058401-A1 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | TRPV1, TRPA1, OPRK1 | TRPV1 1/4885CLK4 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.